These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18355689)

  • 41. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome.
    Turjanski N; Sawle GV; Playford ED; Weeks R; Lammerstma AA; Lees AJ; Brooks DJ
    J Neurol Neurosurg Psychiatry; 1994 Jun; 57(6):688-92. PubMed ID: 7911827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies.
    Zhou Y; Ye W; Brasić JR; Crabb AH; Hilton J; Wong DF
    Neuroimage; 2009 Feb; 44(3):661-70. PubMed ID: 18930830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.
    Shalgunov V; van Wieringen JP; Janssen HM; Fransen PM; Dierckx RA; Michel MC; Booij J; Elsinga PH
    J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Separating dopamine D
    Smart K; Gallezot JD; Nabulsi N; Labaree D; Zheng MQ; Huang Y; Carson RE; Hillmer AT; Worhunsky PD
    Neuroimage; 2020 Jul; 214():116762. PubMed ID: 32201327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
    Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
    J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of striatal dopamine D2/D3 receptor availability with PET and 18F-desmethoxyfallypride: comparison of imaging protocols suited for clinical routine.
    Amtage F; Spehl TS; Hellwig S; Sahm U; Hellwig B; Reuland P; Weiller C; Weber WA; Winkler C; Meyer PT
    J Nucl Med; 2012 Oct; 53(10):1558-64. PubMed ID: 22899645
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
    Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
    J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Wavelet-aided parametric mapping of cerebral dopamine D2 receptors using the high affinity PET radioligand [11C]FLB 457.
    Cselényi Z; Olsson H; Farde L; Gulyás B
    Neuroimage; 2002 Sep; 17(1):47-60. PubMed ID: 12482067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates.
    Varrone A; Stepanov V; Nakao R; Tóth M; Gulyás B; Emond P; Deloye JB; Vercouillie J; Stabin MG; Jonsson C; Guilloteau D; Halldin C
    J Nucl Med; 2011 Aug; 52(8):1313-21. PubMed ID: 21764797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys.
    Chefer SI; Kimes AS; Matochik JA; Horti AG; Kurian V; Shumway D; Domino EF; London ED; Mukhin AG
    Neuropsychopharmacology; 2008 Jan; 33(2):270-8. PubMed ID: 17429408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-steady-state measurement of in vivo radioligand binding with positron emission tomography: specificity analysis and comparison with in vitro binding.
    Perlmutter JS; Moerlein SM; Hwang DR; Todd RD
    J Neurosci; 1991 May; 11(5):1381-9. PubMed ID: 1827499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surrogate markers for cerebral blood flow correlate with [¹⁸F]-fallypride binding potential at dopamine D(2/3) receptors in human striatum.
    Cumming P; Xiong G; la Fougère C; Rominger A; Bartenstein P; Buchholz HG; Piel M; Rösch F; Gründer G; Vernaleken I
    Synapse; 2013 Apr; 67(4):199-203. PubMed ID: 23239525
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum.
    Smith CT; Dang LC; Buckholtz JW; Tetreault AM; Cowan RL; Kessler RM; Zald DH
    Transl Psychiatry; 2017 Apr; 7(4):e1091. PubMed ID: 28398340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decreased dopamine D2/D3-receptor binding in temporal lobe epilepsy: an [18F]fallypride PET study.
    Werhahn KJ; Landvogt C; Klimpe S; Buchholz HG; Yakushev I; Siessmeier T; Müller-Forell W; Piel M; Rösch F; Glaser M; Schreckenberger M; Bartenstein P
    Epilepsia; 2006 Aug; 47(8):1392-6. PubMed ID: 16922886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
    Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
    Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the reference tissue models for PET and SPECT benzodiazepine binding parameters.
    Millet P; Graf C; Buck A; Walder B; Ibáñez V
    Neuroimage; 2002 Oct; 17(2):928-42. PubMed ID: 12377167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduced D2/D3 Receptor Binding of Extrastriatal and Striatal Regions in Temporal Lobe Epilepsy.
    Bernedo Paredes VE; Buchholz HG; Gartenschläger M; Breimhorst M; Schreckenberger M; Werhahn KJ
    PLoS One; 2015; 10(11):e0141098. PubMed ID: 26544593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET.
    Mukherjee J; Christian BT; Narayanan TK; Shi B; Collins D
    Brain Res; 2005 Jan; 1032(1-2):77-84. PubMed ID: 15680944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [11C]FLB 457: re-evaluation of the validity of using a cerebellar reference region.
    Asselin MC; Montgomery AJ; Grasby PM; Hume SP
    J Cereb Blood Flow Metab; 2007 Feb; 27(2):378-92. PubMed ID: 16736043
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
    Salama I; Hocke C; Utz W; Prante O; Boeckler F; Hübner H; Kuwert T; Gmeiner P
    J Med Chem; 2007 Feb; 50(3):489-500. PubMed ID: 17266201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.